ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to inv...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-03-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-023-00512-7 |